Q4 2025 Paysign Inc Earnings Call Transcript
Key Points
- PaySign Inc (PAYS) reported a 40.5% increase in revenue for 2025, reaching $82 million.
- Net income nearly doubled, increasing by 98% to $7.6 million, showcasing strong profitability.
- The patient affordability business saw a significant revenue growth of 168% year over year.
- Operating margins improved by 723 basis points, indicating enhanced operational efficiency.
- The company added 55 new programs, expanding its active programs to 131, demonstrating robust growth in client engagement.
- Plasma compensation revenue only grew by 4%, indicating slower growth compared to other segments.
- The company faces potential headwinds from legislative and regulatory changes affecting co-pay programs.
- There is a concern about the impact of direct-to-consumer and pharmacy discount programs on the business model.
- The plasma business is experiencing a decline in average plasma donations per center, affecting revenue per center.
- The company is still awaiting FDA review for its donor management system, which could delay potential growth in the plasma segment.
Good afternoon. My name is Kevin and I'll be your conference operator today. At this time, I'd like to welcome everyone to Paysign Inc's fourth-quarter and full-year 2025 earnings conference call.
After the speaker's prepared remarks, there'll be a question-and-answer session. (Operator Instructions) As a reminder, this conference call is being recorded. The comments on today's call regarding pay sign's financial results will be on a GAAP basis unless otherwise noted.
Paysign's earnings release was disseminated to the SEC earlier today and can be found on the investor relations section of our website PaySign.com, which includes reconciliations of non-GAAP measures to GAAP reported amounts. Additionally, I set forth in more detail in our earnings release, I'd like to remind everyone that today's call will include forward-looking statements regarding Payign's future performance. Actual performance could differ materially from these forward-looking statements. Information about the factors that could affect future performance is summarized at the end of Paysign's earnings release and in our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
